Genomic characterization of Escherichia coli and Enterobacter hormaechei clinical isolates from a tertiary healthcare facility in Kenya

This study characterizes multidrug-resistant *Escherichia coli* and *Enterobacter hormaechei* clinical isolates from a Kenyan tertiary facility using whole-genome sequencing, revealing high-risk clones, diverse resistance mechanisms including blaCTX-M and blaACT genes, and plasmid-mediated links to environmental reservoirs, while noting the absence of carbapenem resistance.

The Gist

Imagine a hospital as a busy fortress. Inside, there are tiny, invisible invaders called bacteria. Most of the time, our "weapons" (antibiotics) can easily defeat them. But in this study, researchers in Kenya found a group of these bacteria that have learned to wear super-armor, making our standard weapons useless.

Here is the story of what they found, explained simply:

1. The Villains: The "Super-Soldiers"

The researchers looked at two specific types of bacteria: E. coli (usually found in the gut) and Enterobacter hormaechei (often found in hospitals).

• The Problem: These weren't just regular bacteria. They were Multidrug-Resistant (MDR). Think of them as soldiers who have found a way to block every single type of shield (antibiotic) the doctors tried to throw at them, except for the very strongest, most expensive ones (carbapenems).
• The Victims: These "super-soldiers" were found in patients who were already weak—people with kidney failure needing dialysis, trauma victims, or elderly patients in the ICU. Because these patients' immune systems were tired, the bacteria had an easy time taking over.

2. The Secret Weapon: The "Genetic Backpacks" (Plasmids)

How did these bacteria get so strong? The researchers used a high-tech microscope (called Nanopore Sequencing) to look at their DNA. They found something fascinating: Plasmids.

• The Analogy: Imagine the bacteria's main DNA is like a hard drive with its basic operating system. But these bacteria also carry backpacks (plasmids).
• What's in the backpack? Inside these backpacks are "cheat codes" or "instruction manuals" that tell the bacteria how to build armor against antibiotics.
• The Scary Part: These backpacks are portable. One bacteria can hand its backpack to another, and suddenly, the second bacteria becomes a super-soldier too. This is called "horizontal gene transfer." It's like one student in a classroom suddenly getting a cheat sheet and handing it to the whole class before the teacher even notices.

3. The "Double Trouble" Backpacks

The researchers found that these backpacks weren't just carrying antibiotic resistance. They were also carrying metal resistance.

• The Metaphor: Imagine the backpack has a compartment for "Anti-Antibiotic Shields" and another compartment for "Anti-Mercury/Arsenic Shields."
• Why does this matter? Hospitals and the environment often have traces of heavy metals (from cleaning chemicals or industrial waste). If the bacteria need to survive the metal, they keep the backpack. And because the backpack is one big package, they also keep the antibiotic resistance. It's a "buy one, get one free" deal for the bacteria: survive the metal, and you automatically survive the medicine too.

4. The "Global Travelers"

The researchers compared the DNA of these Kenyan bacteria to a giant global library of bacteria from around the world.

• The Discovery: They found that the "backpacks" in Kenya were almost identical to backpacks found in China, Switzerland, Japan, and the USA.
• The Lesson: This means these super-bacteria (or their dangerous backpacks) are traveling the world. They might have started in a hospital sink in Kenya, a farm in the US, or a wastewater plant in Japan, and they are swapping genetic material globally. The environment (water, soil, sinks) acts as a giant mixing bowl where these bacteria swap their cheat codes.

5. The "High-Risk" Clones

The study identified two specific "families" of bacteria that are particularly dangerous:

• ST1193 (The E. coli Family): A notorious global criminal known for causing infections in the blood and urinary tract.
• ST78 (The Enterobacter Family): A master thief known for stealing and spreading resistance genes.
  Finding these specific families in Kenya is a warning sign that the most dangerous strains are already here.

6. The Good News and The Bad News

• The Good News: None of these bacteria were resistant to the "nuclear option" antibiotics (carbapenems) yet. We still have a few weapons left.
• The Bad News: They are carrying the blueprints to build resistance to those last-line weapons. If they pick up just one more "backpack" from the environment, they could become untreatable.

The Bottom Line

This paper is a wake-up call. It shows that in Kenya, dangerous bacteria are already evolving, swapping genetic "cheat codes" in hospitals, and connecting with bacteria from all over the world.

What needs to happen?

1. Stop the Swapping: We need better infection control (cleaning, hand washing) to stop the bacteria from meeting and swapping backpacks.
2. Use Weapons Wisely: Doctors need to be careful not to overuse antibiotics, which forces the bacteria to evolve faster.
3. Watch the Environment: We can't just look at sick patients; we need to check the water, soil, and hospital sinks, because that's where the bacteria are practicing their tricks.

In short: The bacteria are getting smarter and sharing their secrets faster than we are. We need to upgrade our defenses before they unlock the final door.

Technical Summary

1. Problem Statement

Antimicrobial resistance (AMR), particularly among Extended-Spectrum Beta-Lactamase-producing Enterobacterales (ESBL-E), is a critical public health challenge in low- and middle-income countries (LMICs) like Kenya. While short-read sequencing is the gold standard for genomic surveillance, it often fails to resolve repetitive regions and reconstruct complete plasmids, which are crucial for understanding the horizontal transfer of resistance genes. There is a need for cost-effective, portable genomic surveillance in resource-limited settings to track high-risk clones and mobile genetic elements (MGEs) that drive the spread of multidrug resistance (MDR) in clinical environments.

2. Methodology

• Study Design & Sampling: The study analyzed 7 multidrug-resistant (MDR) clinical isolates collected between March and November 2021 from Thika Level Five Hospital, Kenya. The isolates included four Escherichia coli and three Enterobacter hormaechei.
• Phenotypic Characterization: Antimicrobial susceptibility testing (AST) was performed using the Kirby-Bauer disk diffusion method against 20 antibiotics (including carbapenems, cephalosporins, fluoroquinolones, and aminoglycosides) following CLSI 2020 guidelines.
• Sequencing Technology:
  • Platform: Oxford Nanopore Technologies (ONT) MinION (R9.5 flow cell).
  • Library Prep: SQK-LSK109 ligation sequencing kit with native barcoding.
  • Duration: 48-hour sequencing runs.
• Bioinformatics Pipeline:
  • Basecalling & QC: Guppy (v6.4.6) for basecalling; Porechop for adapter trimming; Filtlong for read filtering (>500 bp).
  • Assembly: De novo assembly using Flye (v2.9.1).
  • Polishing: A three-step polishing strategy using Racon (4 rounds), Medaka (v1.7.2), and Homopolish.
  • Annotation & Analysis: Prokka for annotation; PubMLST and ANI for species/strain identification; Resfinder (v4.6.0) and PlasmidFinder for ARG and replicon detection; MOB-suite for plasmid reconstruction.
  • Comparative Genomics: BLASTn against NCBI databases and phylogenetic analysis of plasmids.

3. Key Results

A. Phenotypic Resistance Profiles

• All isolates exhibited resistance to third-generation cephalosporins (Ceftriaxone, Cefotaxime) and fluoroquinolones.
• All isolates remained susceptible to carbapenems (Imipenem and Meropenem); no carbapenemase genes were detected.
• Resistance patterns varied by species and sample source (urine, stool, pus).

B. Escherichia coli Genomic Characterization

• Clonal Lineages: Identified Sequence Types (ST) included ST1193 (high-risk clone, found in 2 isolates), ST53, and ST12270.
• Phylogroup & Serotype: All isolates belonged to the virulent Phylogroup B2. The dominant serovar was O75:H5.
• Chromosomal Resistance:
  • All isolates harbored the ESBL gene blaCTX-M-15 on the chromosome.
  • Point mutations conferring fluoroquinolone resistance were found in gyrA, parC, and parE genes.
  • Mutations in rpoB (conferring rifampicin resistance) were also detected.
• Plasmid Analysis:
  • Multiple plasmids were reconstructed, carrying genes for tetracycline, aminoglycosides, macrolides, and beta-lactams.
  • Co-resistance: Plasmids frequently carried metal resistance operons (specifically mercury: merA, merR, merT, merP, merC), suggesting co-selection pressure from heavy metals.
  • Global Linkage: BLAST analysis showed >95% similarity between Kenyan plasmids and those isolated from China, Switzerland, Kazakhstan, and the USA, indicating global dissemination via environmental and clinical reservoirs.

C. Enterobacter hormaechei Genomic Characterization

• Clonal Lineages: Isolates belonged to ST88, ST98, and the high-risk clone ST78.
• Chromosomal Resistance: All isolates encoded the chromosomal AmpC beta-lactamase blaACT. Isolates S08 and S09 also carried fosA (fosfomycin resistance).
• Plasmid Analysis:
  • Plasmids carried diverse ARGs including blaCTX-M, blaTEM, blaOXA, and genes for aminoglycoside and chloramphenicol resistance.
  • Metal Resistance: Plasmids from ST78 and other isolates carried arsenic and mercury resistance operons.
  • Environmental Connection: Plasmids showed high identity to sequences from wastewater (Japan), feedlots (USA), and clinical samples (China), highlighting the hospital-environment interface.

4. Key Contributions

1. Application of ONT in LMICs: Demonstrated the feasibility of using portable, long-read Oxford Nanopore sequencing for rapid, cost-effective genomic surveillance of MDR pathogens in a Kenyan tertiary hospital.
2. Resolution of Mobile Genetic Elements: Successfully reconstructed complete plasmids, revealing the co-localization of antibiotic resistance genes (ARGs) and metal resistance operons, a feature often missed by short-read sequencing.
3. Identification of High-Risk Clones: Confirmed the presence of globally significant high-risk clones (ST1193 in E. coli and ST78 in E. hormaechei) in the Kenyan clinical setting.
4. One Health Insight: Provided genomic evidence linking clinical isolates to environmental sources (wastewater, feedlots) and international strains, underscoring the role of environmental reservoirs in AMR transmission.

5. Significance and Implications

• Clinical Impact: The study highlights that while carbapenem resistance is currently absent, the accumulation of ESBLs (CTX-M, ACT, OXA) and fluoroquinolone resistance severely limits treatment options for vulnerable populations, particularly End-Stage Renal Disease (ESRD) patients and trauma victims.
• Surveillance Strategy: The findings advocate for the integration of genomic surveillance into routine AMR monitoring in LMICs to detect emerging high-risk clones early.
• Infection Control: The presence of identical plasmids in clinical and environmental samples suggests that infection prevention and control (IPC) measures must extend beyond hospital wards to include environmental sanitation to break the cycle of transmission.
• Stewardship: The data supports the urgent need for antimicrobial stewardship programs to prevent the selection of further resistance, particularly given the co-selection pressure from heavy metals.

Conclusion: The paper establishes a critical baseline for AMR in Kenya, revealing a complex landscape of chromosomal and plasmid-mediated resistance driven by high-risk clones and facilitated by mobile genetic elements shared between clinical and environmental niches.